20 Is The Loneliest Number: FDA Disease Meeting Schedule Leaves Some Worried About Exclusion
This article was originally published in The Pink Sheet Daily
Executive Summary
Conflict among groups with conditions both included and not included in the preliminary list of public meeting topics prompts FDA to reiterate that the diseases will be selected because better clinical measures are needed, not because the agency will prioritize them over others.